Leerink Partners Maintains Outperform on Veracyte, Raises Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners has maintained an 'Outperform' rating on Veracyte and raised its price target from $35 to $40, indicating confidence in the company's future performance.
October 17, 2024 | 2:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Leerink Partners has increased its price target for Veracyte from $35 to $40 while maintaining an 'Outperform' rating, suggesting a positive outlook for the company's stock.
The increase in price target from $35 to $40 by Leerink Partners, along with the maintained 'Outperform' rating, indicates a strong positive sentiment towards Veracyte's future performance. This is likely to boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100